This is the report of a post hoc updated analysis of efficacy and safety from the randomized phase 3 IMbrave150 trial, demonstrating the efficacy of first-line atezolizumab plus bevacizumab over sorafenib for patients with unresectable HCC. 501 patients were randomized 2:1 to receive 1,200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks or 400 mg sorafenib orally twice daily. After a median follow-up of 15.6 (range 0-28.6) months, median OS was 19.2 months (95%CI 17.0-23.7) with atezolizumab plus bevacizumab and 13.4 months (95%CI 11.4-16.9) with sorafenib (HR 0.66; 95%CI 0.52-0.85; descriptive p<0.001). Median PFS was 6.9 (95%CI 5.7-8.6) and 4.3 (95%CI 4.0-5.6) months in the respective treatment groups (HR 0.65; 95%CI 0.53-0.81; descriptive p<0.001). Treatment-related grade 3/4 adverse events occurred in 143 (43%) of 329 and 72 (46%) of 156 safety-evaluable patients in the respective groups, and treatment-related grade 5 events occurred in 6 (2%) and 1 (<1%) patients.

(Cheng, Al., et al. – J Hepatol, April 2022)

Read more